Company profile: Verge Genomics
1.1 - Company Overview
Company description
- Provider of an AI-powered, all-in-human drug discovery platform (CONVERGE®) integrating proprietary human genomics and computational tools to predict new drugs; developer of VRG50635, a PIKfyve inhibitor for ALS; and collaborator with industry and academic partners, including Alexion/AstraZeneca Rare Disease, Eli Lilly, and SITraN, to co-develop clinical-stage and novel therapies.
Products and services
- VRG50635: A clinical-stage small molecule PIKfyve inhibitor engineered to treat amyotrophic lateral sclerosis (ALS), discovered via the CONVERGE platform using human genomics-driven target identification
- CONVERGE® Platform: An all-in-human drug discovery system integrating proprietary human genomics and computational tools to predict new drugs and accelerate discovery using human-derived datasets
- Drug Discovery (Eli Lilly collaboration): A three-year industry-partnered program architected to research and develop novel therapies through rigorous co-development with Eli Lilly and Company
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Verge Genomics
Psomagen
HQ: United States
Website
- Description: Provider of genomics services for research, clinical, and direct-to-consumer applications, including whole genome sequencing, targeted sequencing, Illumina-compatible library runs as flow cell or lane units with full quality control and sample multiplexing, and genetic testing panels to identify gene, chromosome, or protein changes to help confirm or rule out genetic conditions and assess disease risk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Psomagen company profile →
Tavec Pharma
HQ: Canada
Website
- Description: Provider of injectable cancer therapies using exosome-mediated delivery technology. The company enables delivery by injection of anti-cancer molecules, including regulatory RNA, directly to cancer cells to disrupt growth and metastasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tavec Pharma company profile →
CellforCure
HQ: France
Website
- Description: Provider of advanced therapy medicinal product expertise as a key industrial and innovative player in the field.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CellforCure company profile →
MyoNexus Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage gene therapies for limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children’s Hospital; RNA exon-skipping technologies for rare diseases, particularly Duchenne muscular dystrophy, using PMO with next-generation PPMO in development; gene editing research; and precision genetic medicine platforms for Charcot-Marie-Tooth disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MyoNexus Therapeutics company profile →
GenoKey
HQ: Denmark
Website
- Description: Provider of AI-driven combinatorial analytics of genomic and clinical data via the PrecisionLife Innovation Engine to discover novel drug targets, identify drug repositioning candidates, and design diagnostic, prognostic and theranostic clinical decision support tools. Offers precision biopharma and healthcare solutions, including combinatorial risk scores to predict and prevent chronic diseases such as dementia, diabetes and cardiovascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenoKey company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Verge Genomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Verge Genomics
2.2 - Growth funds investing in similar companies to Verge Genomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Verge Genomics
4.2 - Public trading comparable groups for Verge Genomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →